Barriers to Pre-Exposure Prophylaxis (PrEP) access persist in Puerto Rico, causing a significant lag in the island’s primary HIV prevention strategy. According to public health reports, these systemic obstacles hinder the distribution of medication designed to prevent HIV infection among high-risk populations.
Why is PrEP access lagging in Puerto Rico?
Public health reports indicate that the strategy to implement PrEP is experiencing a “rezago,” or lag, due to persistent barriers to access. While the medication is a cornerstone of modern HIV prevention, the reports suggest that logistical or systemic hurdles within Puerto Rico are preventing the prevention strategy from reaching its full potential.
What is PrEP and how does it work?
PrEP is a course of antiretroviral drugs taken by people who are HIV-negative but at high risk of contracting the virus. When taken as prescribed, it reduces the risk of getting HIV from sex or injection drug use. Public health agencies utilize PrEP as a preventative tool to lower the overall incidence of new infections within a community.
What are the implications for the island?
The persistence of these access barriers means that high-risk individuals may remain unprotected despite the existence of the medical technology. According to health reports, addressing these gaps is necessary for the success of the broader HIV prevention strategy in Puerto Rico.
